An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Public ClinicalTrials.gov record NCT05809531. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Study identification
- NCT ID
- NCT05809531
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
- C3 Glomerulonephritis
- C3 Glomerulopathy
- C3G
- Complement 3 Glomerulonephritis
- Complement 3 Glomerulopathy
- Complement 3 Glomerulopathy (C3G)
- DDD
- Dense Deposit Disease
- IC-MPGN
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
- Membranoproliferative Glomerulonephritis
- Membranoproliferative Glomerulonephritis (MPGN)
Interventions
- Pegcetacoplan Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 28, 2023
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
- Last update posted
- Apr 1, 2026
2023 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Academic Medical Research Institute (01034) | Los Angeles | California | 90022 | — |
| Children's Hospital Colorado (01037) | Aurora | Colorado | 80045 | — |
| University of Florida, Department of Pediatric Nephrology (01010) | Gainsville | Florida | 32610 | — |
| Emory Investigational Drug Service (01021) | Atlanta | Georgia | 30322 | — |
| University of Iowa Hospital and Clinics (01030) | Iowa City | Iowa | 52242 | — |
| University of Michigan Hospital (01008) | Ann Arbor | Michigan | 48109 | — |
| Hackensack Meridian Health (01036) | Hackensack | New Jersey | 07601 | — |
| Cohen Children Hospital, Pediatric Pharmacy (01022) | Hyde Park | New York | 11040 | — |
| Columbia Nephrology (01039) | New York | New York | 10032 | — |
| Oregon Health & Science Univ., Dept. Pediatrics (01038) | Portland | Oregon | 97239 | — |
| Northeast Clinical Research Center LLC (01009) | Bethlehem | Pennsylvania | 18017 | — |
| Texas Children's Hospital (01027) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05809531, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05809531 live on ClinicalTrials.gov.